These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 32643793)

  • 1. Therapeutic applications of chelating drugs in iron metabolic disorders of the brain and retina.
    Shahandeh A; Bui BV; Finkelstein DI; Nguyen CTO
    J Neurosci Res; 2020 Oct; 98(10):1889-1904. PubMed ID: 32643793
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Iron chelation and neuroprotection in neurodegenerative diseases.
    Li X; Jankovic J; Le W
    J Neural Transm (Vienna); 2011 Mar; 118(3):473-7. PubMed ID: 21161300
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Iron: a new target for pharmacological intervention in neurodegenerative diseases.
    Whitnall M; Richardson DR
    Semin Pediatr Neurol; 2006 Sep; 13(3):186-97. PubMed ID: 17101458
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The potential application of iron chelators for the treatment of neurodegenerative diseases.
    Hider RC; Roy S; Ma YM; Le Kong X; Preston J
    Metallomics; 2011 Mar; 3(3):239-49. PubMed ID: 21344071
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Conservative iron chelation for neurodegenerative diseases such as Parkinson's disease and amyotrophic lateral sclerosis.
    Devos D; Cabantchik ZI; Moreau C; Danel V; Mahoney-Sanchez L; Bouchaoui H; Gouel F; Rolland AS; Duce JA; Devedjian JC;
    J Neural Transm (Vienna); 2020 Feb; 127(2):189-203. PubMed ID: 31912279
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neurodegenerative diseases and therapeutic strategies using iron chelators.
    Ward RJ; Dexter DT; Crichton RR
    J Trace Elem Med Biol; 2015; 31():267-73. PubMed ID: 25716300
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting Iron Dyshomeostasis for Treatment of Neurodegenerative Disorders.
    Bergsland N; Tavazzi E; Schweser F; Jakimovski D; Hagemeier J; Dwyer MG; Zivadinov R
    CNS Drugs; 2019 Nov; 33(11):1073-1086. PubMed ID: 31556017
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ironing iron out in Parkinson's disease and other neurodegenerative diseases with iron chelators: a lesson from 6-hydroxydopamine and iron chelators, desferal and VK-28.
    Youdim MB; Stephenson G; Ben Shachar D
    Ann N Y Acad Sci; 2004 Mar; 1012():306-25. PubMed ID: 15105275
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neuroprotective multifunctional iron chelators: from redox-sensitive process to novel therapeutic opportunities.
    Weinreb O; Amit T; Mandel S; Kupershmidt L; Youdim MB
    Antioxid Redox Signal; 2010 Sep; 13(6):919-49. PubMed ID: 20095867
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Green tea catechins as brain-permeable, non toxic iron chelators to "iron out iron" from the brain.
    Mandel S; Weinreb O; Reznichenko L; Kalfon L; Amit T
    J Neural Transm Suppl; 2006; (71):249-57. PubMed ID: 17447435
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of iron in brain ageing and neurodegenerative disorders.
    Ward RJ; Zucca FA; Duyn JH; Crichton RR; Zecca L
    Lancet Neurol; 2014 Oct; 13(10):1045-60. PubMed ID: 25231526
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mini-Review: Is iron-mediated cell death (ferroptosis) an identical factor contributing to the pathogenesis of some neurodegenerative diseases?
    Viktorinova A; Durfinova M
    Neurosci Lett; 2021 Feb; 745():135627. PubMed ID: 33440237
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Iron Chelation in Movement Disorders: Logical or Ironical.
    Kulshreshtha D; Ganguly J; Jog M
    Can J Neurol Sci; 2021 Nov; 48(6):752-759. PubMed ID: 33397531
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Understanding the Role of Hypoxia Inducible Factor During Neurodegeneration for New Therapeutics Opportunities.
    Merelli A; Rodríguez JCG; Folch J; Regueiro MR; Camins A; Lazarowski A
    Curr Neuropharmacol; 2018; 16(10):1484-1498. PubMed ID: 29318974
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Iron chelating strategies in systemic metal overload, neurodegeneration and cancer.
    Gumienna-Kontecka E; Pyrkosz-Bulska M; Szebesczyk A; Ostrowska M
    Curr Med Chem; 2014; 21(33):3741-67. PubMed ID: 25005181
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel bifunctional drugs targeting monoamine oxidase inhibition and iron chelation as an approach to neuroprotection in Parkinson's disease and other neurodegenerative diseases.
    Youdim MB; Fridkin M; Zheng H
    J Neural Transm (Vienna); 2004 Oct; 111(10-11):1455-71. PubMed ID: 15480846
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel therapeutic approach for neurodegenerative pathologies: multitarget iron-chelating drugs regulating hypoxia-inducible factor 1 signal transduction pathway.
    Weinreb O; Amit T; Mandel S; Youdim MB
    Neurodegener Dis; 2012; 10(1-4):112-5. PubMed ID: 22156453
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Iron chelation in the treatment of neurodegenerative diseases.
    Dusek P; Schneider SA; Aaseth J
    J Trace Elem Med Biol; 2016 Dec; 38():81-92. PubMed ID: 27033472
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nanoparticle iron chelators: a new therapeutic approach in Alzheimer disease and other neurologic disorders associated with trace metal imbalance.
    Liu G; Men P; Harris PL; Rolston RK; Perry G; Smith MA
    Neurosci Lett; 2006 Oct; 406(3):189-93. PubMed ID: 16919875
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Green tea catechins as brain-permeable, natural iron chelators-antioxidants for the treatment of neurodegenerative disorders.
    Mandel S; Amit T; Reznichenko L; Weinreb O; Youdim MB
    Mol Nutr Food Res; 2006 Feb; 50(2):229-34. PubMed ID: 16470637
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.